Deferasirox (ICL670A) effectively inhibits oesophageal cancer growthin vitroandin vivo-Reference-Cited by-同舟云学术

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growthin vitroandin vivo

Published:2013-02-25 Issue:6 Volume:168 Page:1316-1328
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Ford SJ¹,Obeidy P²,Lovejoy DB²,Bedford M¹,Nichols L¹,Chadwick C¹,Tucker O¹,Lui GYL²,Kalinowski DS²,Jansson PJ²,Iqbal TH¹,Alderson D¹,Richardson DR²,Tselepis C¹

Affiliation:

1. School of Cancer Sciences; Department of Medical & Dental Sciences; University of Birmingham; Birmingham; UK

2. Department of Pathology and Bosch Institute; University of Sydney; Sydney; NSW; Australia

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.12045/fullpdf

Reference54 articles.

1. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma;Boult;Clin Cancer Res,2008

2. A role for iron in Wnt signalling;Brookes;Oncogene,2008

3. Cancer Research UK (CRUK) 2012 Oesophageal cancer statistics http://info.cancerresearchuk.org/cancerstats/types/oesophagus/

4. Long-term efficacy and safety of deferasirox;Cappellini;Blood Rev,2008

5. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox;Chantrel-Groussard;Eur J Pharmacol,2006

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulating metalloimmunology with nanomedicine for cancer therapy;Nano Research;2023-11-07

2. Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators;Cancers;2023-01-12

3. A DFX-based iron nanochelator for cancer therapy;Frontiers in Bioengineering and Biotechnology;2022-11-28

4. Puzzling out iron complications in cancer drug resistance;Critical Reviews in Oncology/Hematology;2022-10

5. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo;Gynecologic Oncology;2022-07